The ITGB1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from A-549 human lung adenocarcinoma epithelial cells. This product provides a loss-of-function model through targeted disruption of the ITGB1 gene, which encodes the integrin beta-1 subunit. The polyclonal population comprises a heterogeneous mixture of edited cells, each carrying distinct mutations at the ITGB1 locus, enabling robust gene knockout without single-cell cloning. This polyclonal knockout model is well-suited for studies requiring bulk populations that avoid clonal selection biases and maintain genetic diversity representative of the original parental line.
The A-549 host cell line is a widely utilized model in respiratory disease research, originally established from lung carcinoma tissue of a 58-year-old Caucasian male. These adherent epithelial cells exhibit morphological and molecular features characteristic of lung adenocarcinoma. A-549 cells are commonly employed to investigate lung cancer biology, including proliferation, metastasis, and drug response, making them an appropriate background for exploring integrin function in pulmonary malignancies.
Integrin beta-1 (ITGB1) functions as the obligate beta subunit that pairs with alpha integrins to form heterodimeric receptors for extracellular matrix (ECM) proteins. Upon ligand binding, ITGB1-containing integrins recruit and activate focal adhesion kinase (FAK) and Src family kinases, initiating a cascade involving PI3K, Akt, ERK1/2, and Rho GTPases. This signaling axis is regulated by upstream factors such as TGF-??, EGF, and TNF-??, and facilitated by cytoplasmic adaptors Talin, Kindlin, Paxillin, and Vinculin. Downstream effectors YAP/TAZ and matrix metalloproteinases (MMPs) further coordinate transcriptional and proteolytic responses, controlling cell adhesion, migration, proliferation, and survival.
In the context of A-549 cells, ITGB1 is known to promote aggressive cancer cell behaviors. Knockout of ITGB1 disrupts integrin-mediated attachment and signaling, providing a powerful system to dissect the contribution of beta-1 integrins to lung adenocarcinoma progression. This model allows researchers to examine how loss of ITGB1 affects anchorage-dependent growth, anoikis resistance, invasive capacity, and sensitivity to chemotherapeutic agents. Given the established role of ITGB1 in mediating drug resistance and metastatic spread, these knockout cells offer a valuable platform for identifying downstream vulnerabilities and evaluating integrin-targeted therapies.
Typical applications of the ITGB1 Knockout A-549 Polyclonal Cells include Western blot analysis of ITGB1 and downstream phospho-proteins, cell adhesion assays to fibronectin, Boyden chamber migration and invasion assays, wound healing assays, flow cytometric assessment of integrin surface expression, immunofluorescence staining of focal adhesions, co-immunoprecipitation of integrin complexes, and RT-qPCR quantification of integrin pathway genes. These cells are also suitable for high-throughput screens identifying integrin inhibitors. For further information, please contact Ascent Research.
